GlassScriptPhysician profile
Stafford D John
NPI 1508842261
$3,033.45
in general payments reported to CMS, 2019-2025
15 companies · $739 in 2025
The $739 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14.62 · 2020: $31.00 · 2021: $547 · 2022: $430 · 2023: $743 · 2024: $529 · 2025: $739.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,010.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,010.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $738.11 | 2022-2024 | Lupkynis |
| Travere Therapeutics, INC. | $500.25 | 2023-2025 | Filspari |
| Astrazeneca Pharmaceuticals LP | $429.99 | 2019-2023 | Farxiga |
| Vifor Pharma, INC. | $254.32 | 2021-2025 | Veltassa |
| Glaxosmithkline, LLC. | $221.24 | 2023 | Benlysta |
| Akebia Therapeutics INC | $186.68 | 2020-2025 | Vafseo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $140.55 | 2025 | Jardiance |
| Calliditas Therapeutics US INC. | $124.82 | 2025 | Tarpeyo |
| Bayer Healthcare Pharmaceuticals INC. | $118.40 | 2022 | |
| Ani Pharmaceuticals, INC. | $106.32 | 2023 | Purified Cortrophin Gel |
| Fresenius USA Marketing, INC. | $64.44 | 2025 | Velphoro |
| Novartis Pharmaceuticals Corporation | $54.50 | 2024-2025 | |
| Nxstage Medical, INC. | $45.03 | 2022 | |
| Horizon Therapeutics Plc | $33.22 | 2021-2022 | |
| Novo Nordisk INC | $15.58 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stafford John listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.